Nasopharyngeal and serological anti SARS-CoV-2 IgG/IgA responses in COVID-19 patients.
Mucosal Immunity
SARS CoV
Serology
Journal
Journal of clinical virology plus
ISSN: 2667-0380
Titre abrégé: J Clin Virol Plus
Pays: England
ID NLM: 9918283581506676
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
03
04
2021
revised:
13
08
2021
accepted:
22
09
2021
entrez:
9
3
2022
pubmed:
10
3
2022
medline:
10
3
2022
Statut:
ppublish
Résumé
The systemic antibody responses to SARS-CoV-2 in COVID-19 patients has been extensively studied. However, less is known about the mucosal responses in the upper airways, the site of initial SARS-CoV-2 replication. The IgG and IgA antibody responses were analysed in plasma and nasopharyngeal swabs from the first four confirmed COVID-19 patients in France. Two were pauci-symptomatic while two developed severe disease. We characterized their antibody profiles by using an in-house ELISA to detect antibodies directed against SARS-CoV-2 Nucleoprotein and Spike. Anti-N IgG and IgA antibodies were detected in the NPS of severe patients only. The levels of antibodies in the plasma markedly differed amongst the patients. The most distinctive features are a strong anti-N IgG response in the severe patient who recovered, and a high anti-N IgA response specifically detected in the fatal case of COVID-19. Anti-N IgG and IgA antibodies are detected in NPS only for severe patients, with levels related to serological antibodies. The severe patients showed different antibody profiles in the plasma, notably regarding the IgA and IgG response to the N antigen, that may reflect different disease outcome. By contrast, pauci-symptomatic patients did not exhibit any mucosal antibodies in NSP, which is associated with a low or absent serological response against both N and S.
Sections du résumé
Background
UNASSIGNED
The systemic antibody responses to SARS-CoV-2 in COVID-19 patients has been extensively studied. However, less is known about the mucosal responses in the upper airways, the site of initial SARS-CoV-2 replication.
Methods
UNASSIGNED
The IgG and IgA antibody responses were analysed in plasma and nasopharyngeal swabs from the first four confirmed COVID-19 patients in France. Two were pauci-symptomatic while two developed severe disease. We characterized their antibody profiles by using an in-house ELISA to detect antibodies directed against SARS-CoV-2 Nucleoprotein and Spike.
Results
UNASSIGNED
Anti-N IgG and IgA antibodies were detected in the NPS of severe patients only. The levels of antibodies in the plasma markedly differed amongst the patients. The most distinctive features are a strong anti-N IgG response in the severe patient who recovered, and a high anti-N IgA response specifically detected in the fatal case of COVID-19.
Conclusions
UNASSIGNED
Anti-N IgG and IgA antibodies are detected in NPS only for severe patients, with levels related to serological antibodies. The severe patients showed different antibody profiles in the plasma, notably regarding the IgA and IgG response to the N antigen, that may reflect different disease outcome. By contrast, pauci-symptomatic patients did not exhibit any mucosal antibodies in NSP, which is associated with a low or absent serological response against both N and S.
Identifiants
pubmed: 35262023
doi: 10.1016/j.jcvp.2021.100041
pii: S2667-0380(21)00033-8
pmc: PMC8474802
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100041Informations de copyright
© 2021 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
SvdW, BCC and NE have a patent “Use of proteins and peptides coded by the genome of a novel strain of sars associated coronavirus” issued, and SW a patent “Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics” pending. SP, NE, SW and CD applied for a patent which includes claims describing N-based serological diagnosis of COVID. Professor Ghosn reports personal fees from ViiV Healthcare, Gilead Science, Janssen Cilag, and research grants from Gilead Sciences, MSD and ViiV Healthcare, outside the submitted work.
Références
Cell. 2020 Dec 10;183(6):1496-1507.e16
pubmed: 33171099
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9
pubmed: 33221383
J Med Virol. 2021 Apr;93(4):2149-2159
pubmed: 33058220
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Sci Transl Med. 2020 Sep 2;12(559):
pubmed: 32817357
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
PLoS One. 2020 Oct 9;15(10):e0240502
pubmed: 33035234
Nat Rev Immunol. 2020 Jul;20(7):427-441
pubmed: 32015473
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33261718
Mucosal Immunol. 2008 Jan;1(1):11-22
pubmed: 19079156
PLoS One. 2020 Oct 21;15(10):e0241104
pubmed: 33085715
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32430429
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033173